Analyst Ratings for NewAmsterdam Pharma Co NV (NAMS)
NAMS Rating Summary
NAMS Price Target Summary
- Highest: $55.00 (Leerink Partners)
- Lowest: $27.00 (Goldman Sachs)
- Average: $45.70
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$45.70 (+53%)
* Over Last 12-Mos
Rating Score: 9.3 / 10
Percentile Rank: 90%
Avg. $ Target:
$45.70 (+53%)
* Over Last 12-Mos
Rating Score: 9.3 / 10
Percentile Rank: 90%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/20/2025 | H.C. Wainwright | Joseph Pantginis | New Coverage | Buy (N/A) |
52.00 (N/A) |
36.40 (29.86) |
-17.97% | Details |
| 8/25/2025 | Wells Fargo | Yanan Zhu | New Coverage | Overweight (N/A) |
45.00 (N/A) |
25.00 (29.86) |
19.44% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
